Detection of a new melanoma in a patient treated with fingolimod

Area of Science:

• Dermatology
• Neurology
• Oncology

Background:

• Fingolimod is a disease-modifying therapy for relapsing remitting multiple sclerosis.
• Previous studies (TRANSFORMS, FREEDOMS, INFORMS) have rarely reported skin cancer in patients using fingolimod.
• Skin cancers, particularly melanoma, are infrequently observed in multiple sclerosis patients.

Observation:

• A 52-year-old Caucasian female with a 19-year history of relapsing remitting multiple sclerosis was diagnosed with skin cancer.
• The patient had phototype II, no significant history of sun exposure, sunburns, or UV cabin use, and few nevi.
• The diagnosed skin cancer presented with unclassifiable histological characteristics, distinguishing it from typical superficial spreading malignant melanoma.

Findings:

• This case presents a rare instance of unclassifiable skin cancer in a multiple sclerosis patient treated with fingolimod.
• The histological features of this melanoma were atypical compared to previously reported cases.
• The occurrence of skin cancers in multiple sclerosis patients, while exceptional, is an emerging concern.

Implications:

• The findings suggest a potential need for increased vigilance regarding skin cancer development in multiple sclerosis patients.
• Enhanced dermatological surveillance is recommended for patients undergoing treatment with fingolimod.
• Further research is warranted to understand the risk factors and specific types of skin cancers associated with fingolimod therapy.